NIH R01 · 2024
Predicting risk of systemic autoimmune disease in patients with positive antinuclear antibodies
Project Summary Providers across multiple specialties face challenges in determining the clinical significance of a positive antinuclear antibody (ANA). While a positive ANA is highly sensitive for autoimmune disease, it is non-specific with up to 20% of the general population having a positive ANA without having autoimmune disease. Risk models to aide clinicians in stratifying positive ANA patients do not currently exist. By identifying high-risk patients, providers could properly triage patients for prompt treatment to reduce autoimmune disease-related morbidity and mortality. Our long-term goal is to build risk models in the electronic health record (EHR) for autoimmune diseases that…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.